Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules.
BACKGROUND
The tablet formulation of ritonavir-boosted lopinavir (LPV/r; Kaletra) has many advantages over the soft gel capsule (SGC) formulation, including lower pill count, no refrigeration requirement, and no dietary restrictions. These advantages may help improve patient compliance and therefore increase adherence to treatment. However, there are limited data regarding patient preferences and only recently was the comparative efficacy and tolerability data of LPV/r SGC versus tablet formulation presented at an international conference. To address this deficit, we conducted a market research survey to assess potential tolerability benefits, patient satisfaction, changes in adherence, and formulation preference in patients switching from SGCs to the tablet formulation. Data from 332 patients who switched from LPV/r SGCs twice-daily (BID) to tablets BID and 41 patients who switched from LPV/r SGCs BID or once daily (QD) to tablets QD were analyzed.


RESULTS
Switching from SGCs to a tablet formulation of LPV/r was associated with increased patient satisfaction, tolerability and self-reported adherence to treatment; gastrointestinal side effects were reduced. In addition, respondents indicated that they preferred the tablet formulation to the SGC.


CONCLUSIONS
The LPV/r tablet formulation provides HIV-infected patients with multiple benefits over the SGC in terms of tolerability and convenience. Additional assessments to further define the tolerability profile of the LPV/r tablet, including studies using once-daily dosing, are warranted.
Schrader
Shannon
S
Abbott Virology, Abbott Laboratories, Abbott Park, USA.
Chuck
Susan K
SK
Rahn
Laurie W
LW
Parekh
Paras
P
Emrich
Katherine G
KG
N Engl J Med. 2002 Jun 27;346(26):2039-46
12087139
Lancet. 2007 Jul 7;370(9581):49-58
17617272
Curr Med Res Opin. 2005 Oct;21(10):1683-92
16238909
AIDS Patient Care STDS. 2005 Dec;19(12):794-802
16375611
Lancet. 2006 Aug 5;368(9534):476-82
16890834
J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):153-60
16951643
J Infect Dis. 2004 Jan 15;189(2):265-72
14722892
Int J STD AIDS. 2002 Sep;13(9):593-601
12230922
AIDS. 2005 Jul 22;19(11):1233-4
15990580
J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):401-10
17224848
AIDS. 2006 Mar 21;20(5):711-8
16514301